Teva Launches AHZANTIVE Aflibercept Biosimilar Across Four European Markets Following EC Approval

Teva Pharmaceutical Industries' commercial rollout of AHZANTIVE (aflibercept) into France, Germany, Spain, and the Netherlands signals how biosimilar manufacturers are sequencing multi-market launches under semi-exclusive partnership structures, a model with direct implications for QA, supply chain, and regulatory teams managing parallel market entries.

Pre-filled syringe shipments began in May 2026, following European Commission approval in 2025 for four retinal indications: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and macular edema secondary to retinal vein occlusion (RVO). The EMA dossier established biosimilarity in efficacy, safety, and immunogenicity against the reference product, Eylea (aflibercept), consistent with the analytical and clinical comparability standards expected under current EMA biosimilar guidelines.

The commercialization structure is notable for operations leads. Teva holds a semi-exclusive agreement with Klinge Biopharma GmbH and Formycon AG covering major European markets and Israel, a tripartite arrangement that distributes commercial risk while concentrating supply obligations. For manufacturers considering similar partnership models, the AHZANTIVE rollout illustrates how batch release scheduling, serialization compliance, and country-level pharmacovigilance responsibilities must be allocated contractually before first shipment, not after.

Teva has indicated further market launches are planned for later in 2026. For QA directors and regulatory affairs leads at competing biosimilar programs, the sequencing choice, prioritizing high-volume markets with established reimbursement frameworks before extending to smaller EU member states, reflects a pragmatic approach to managing post-approval variation submissions and national pricing negotiations concurrently. Each additional market entry carries its own labeling, artwork, and batch documentation requirements under 21 CFR Part 211 equivalents and EU GMP Annex 16 release obligations.

Teva currently holds 11 biosimilars on market globally, with 13 in pipeline across oncology, immunology, ophthalmology, and respiratory. The ophthalmology entry broadens a portfolio that has historically concentrated in immunology and oncology, and it positions the company ahead of anticipated biosimilar competition in the VEGF-inhibitor class as additional reference product exclusivities expire across European jurisdictions.

The measurable checkpoint for this program will be reimbursement uptake rates across the four launch markets by end of 2026, which will determine whether the semi-exclusive partnership model accelerates or constrains volume relative to direct-commercialization alternatives.

Source: Teva Pharmaceutical Industries Ltd. via GlobeNewswire, 4 June 2026.